Sangamo Biosciences (NASDAQ: SGMO) reported Q2 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13). Revenue for the quarter came in at $8.4 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.